Menu
Search
|

Menu

Close
X

Sophiris Bio Inc SPHS.OQ (NASDAQ Stock Exchange Capital Market)

3.09 USD
-0.06 (-1.90%)
As of Jul 20
chart
Previous Close 3.15
Open 3.17
Volume 8,985
3m Avg Volume 62,656
Today’s High 3.17
Today’s Low 3.07
52 Week High 4.04
52 Week Low 1.80
Shares Outstanding (mil) 30.11
Market Capitalization (mil) 70.63
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 5 analysts

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
0
FY16
0
FY15
0
EPS (USD)
FY18
-0.111
FY17
-0.287
FY16
-0.530
FY15
-0.842
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.76
Price to Sales (TTM)
vs sector
--
5.73
Price to Book (MRQ)
vs sector
5.34
5.47
Price to Cash Flow (TTM)
vs sector
--
23.29
Total Debt to Equity (MRQ)
vs sector
0.00
16.84
LT Debt to Equity (MRQ)
vs sector
0.00
12.51
Return on Investment (TTM)
vs sector
-47.03
14.61
Return on Equity (TTM)
vs sector
-97.97
16.34

EXECUTIVE LEADERSHIP

Lars Ekman
Chairman of the Board, Since 2014
Salary: $60,000.00
Bonus: --
Randall Woods
President, Chief Executive Officer, Director, Since 2012
Salary: $450,885.00
Bonus: --
Peter Slover
Chief Financial Officer, Since 2012
Salary: $303,850.00
Bonus: --
Allison Hulme
Chief Operating Officer, Head - Research & Development, Director, Since 2016
Salary: $350,100.00
Bonus: --
John Geltosky
Independent Director, Since 2008
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

1258 Prospect St
LA JOLLA   CA   92037-3609

Phone: +1858.7771760

Sophiris Bio Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing products for the treatment of urological diseases. The Company is developing topsalysin (PRX302) as a treatment for the lower urinary tract symptoms of benign prostatic hyperplasia (BPH) commonly referred to as an enlarged prostate and as a treatment for localized low to intermediate risk prostate cancer. Topsalysin, a genetically modified recombinant protein, is delivered through ultrasound-guided injection directly into the prostate. This membrane-disrupting protein is selectively activated by enzymatically active prostate specific antigen (PSA), which is only present in the prostate, leading to localized cell death and tissue disruption without damage to neighboring tissue and nerves. This method of administration limits the circulation of the drug in the body. The Company has completed Phase III clinical trials of topsalysin.

SPONSORED STORIES